Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
<p>Extended Data relating to Main Figure 4/Targeting of AKT-driven subclonal progression of ALDH1A1+ cells. A, Collected source data for main Figs. 4B,C,F-H. Left, diagrams: in vitro cell confluence dynamics of paired treatment naive vs. TMZ-related experimental (TMZ→eR; BN46) or clinical (RT/...
Đã lưu trong:
| Tác giả chính: | |
|---|---|
| Tác giả khác: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Được phát hành: |
2025
|
| Những chủ đề: | |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| Tóm tắt: | <p>Extended Data relating to Main Figure 4/Targeting of AKT-driven subclonal progression of ALDH1A1+ cells. A, Collected source data for main Figs. 4B,C,F-H. Left, diagrams: in vitro cell confluence dynamics of paired treatment naive vs. TMZ-related experimental (TMZ→eR; BN46) or clinical (RT/TMZ; BN118, BN123, BN132) relapse patient cells. Monitoring of cell confluence by software-based cell recognition. Assay specified in Fig. 4A. Right, graphs: Readout results from the indicated cases in line, representing source data for Figs. 4B (Cell Confluence), 4C (Cell Viability), and 4H (Apoptosis). Respective assays specified in the main Figure Legends. Data as mean ± SD. p values calculated by pairwise Wilcoxon rank-sum test followed by multiple testing correction using Benjamini-Hochberg method. B, IF of ALDH1A1 and Ki67 in the BN46-donor cell tumor PDX model. Shown is an example from a TMZ+MK2206-treated mouse (OS = 148 days; low levels of cellular co-expression). Scale bar: 20 µm. C, Comparison of overall survival under the investigated treatment conditions (refer to Fig. 4J). Hazard ratio 95% confidence interval estimates and significance levels derived from Cox regression are shown.</p> |
|---|